Lilly to bolster gene editing pipeline, buying Verve for up to $1.3B
It appears that Eli Lilly couldn’t wait to get its hands on Verve Therapeutics’ PCSK9 program.
Lilly said Tuesday that it will buy the gene …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
